About FasT Biopharma
FasT Biopharma is a Healthcare company based in Watlington (United Kingdom) founded in 2016 by David Blakey. Optimized antibodies for immuno-oncology are developed by FasT Biopharma. FasT Biopharma has raised $255.66 thousand across 1 funding round from investors including BioCity. The company has 2 employees. FasT Biopharma was last valued at $614.26 thousand in June 2016. Its chief executive, as recorded, is Peter Davis. FasT Biopharma offers products and services including FasL Blocking Therapy. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is FAST BIOPHARMA LTD.
Company details
FasT Biopharma was founded in 2016 and is based in Watlington, United Kingdom. Focus is placed on the biopharmaceutical sector, specifically immuno-oncology. An optimized antibody is developed as the flagship product, FBP002, which remains in the pre-clinical stage. Inhibitory mechanisms are targeted to stimulate immune responses against tumors, with effects on tumor-infiltrating effector cells and reductions in tumor Tregs observed.
- Headquarters Watlington, United Kingdom
- Employees 2
- Founders David Blakey
- SectorsHealthcare
- Website fastbiopharma.com
- Legal Name Fast Biopharma Ltd
- Date of Incorporation 02 Feb, 2016
- Jurisdiction WATLINGTON, OXFORDSHIRE, UNITED KINGDOM
- Total Equity Funding$255.66K (USD)
in 1 rounds
- Latest Funding Round$255.66K (USD), Seed
Jun 2016
- Investors
- Employee Count2
Products & Services of FasT Biopharma
FasT Biopharma offers a comprehensive portfolio of products and services, including FasL Blocking Therapy.
Therapy to prevent cell death in diseases like cancer and blindness
Funding Insights of FasT Biopharma
FasT Biopharma has successfully raised a total of $255.66K through 1 strategic funding round. The most recent funding activity was a Seed round of $255.66 thousand completed in June 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $255,658
- Total Rounds 1
- Last Round Seed — $255,658
- First Round $255,658
(Jun 2016)
- Investors Count 1
All 1 funding rounds of FasT Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2016 | $255,658 | Seed | $614,263 | BioCity | – |
Last known valuation $614,263 (Jun 2016). 1 investors in total: 1 institutional.
Investors in FasT Biopharma
FasT Biopharma has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include BioCity.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life Science focused startup accelerator and incubator | 2002 | biocity.co.uk | Nottingham, United Kingdom |
Investor details for FasT Biopharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of FasT Biopharma
2 people are tracked at FasT Biopharma (2 in leadership); the tracked headcount is 2.
| Name | Role | Group |
|---|---|---|
David Blakey | Co-Founder & CSO | Leadership |
Peter Davis | CEO & Director | Leadership |
Complete people profiles for FasT Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of FasT Biopharma
2 dated milestones of FasT Biopharma, from founding to its latest funding, stage changes and deals.
- Founded FasT Biopharma is founded.
- Funding First funding round of $256K.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about FasT Biopharma
FasT Biopharma was founded in 2016.
FasT Biopharma is headquartered in Watlington, United Kingdom. It is registered at Watlington, Oxfordshire, United Kingdom.
Peter Davis is the CEO of FasT Biopharma, as recorded in our data.
FasT Biopharma is a funded company, having raised a total of $255.66K across 1 funding round to date. The company's 1st funding round was a Seed of $255.66K, raised on Jun 2016.
FasT Biopharma has 2 employees.
FasT Biopharma was founded in 2016 and is based in Watlington, United Kingdom. Focus is placed on the biopharmaceutical sector, specifically immuno-oncology. An optimized antibody is developed as the flagship product, FBP002, which remains in the pre-clinical stage. Inhibitory mechanisms are targeted to stimulate immune responses against tumors, with effects on tumor-infiltrating effector cells and reductions in tumor Tregs observed.
FasT Biopharma offers FasL Blocking Therapy.
FasT Biopharma has 1 investor. Key investors include BioCity.
The valuation of FasT Biopharma is $614.26K as of Jun 2016.
FasT Biopharma operates through Fast Biopharma Ltd.